Stroke Biomarker Panel Development Services

Stroke is a complex and heterogeneous disease with variable infarct size, location and cause. Therefore, a single biomarker may not be sufficient to reflect this underlying complexity. This has led to interest in the use of biomarker panels. In stroke, biomarker panels can provide information on atherosclerosis, thrombosis, inflammation, oxidative stress, endothelial damage, blood-brain barrier disruption, and cerebral ischemia. In addition, multiple markers in a biomarker panel may improve diagnostic sensitivity and specificity.

Fig. 1. Sources of the major candidate biomarkers in stroke. (Dagonnier et al., 2021)

Our Services

Ace Therapeutics offers comprehensive biomarker panel development services to help clients accelerate efficient decision-making and support preclinical studies for stroke drugs. These panels offer a choice of combinations of stroke biomarkers, including multiple panels of proteins, lipids, RNAs and metabolites. To best meet your research goals, these panels can be customized for various applications in the field of stroke.

Stroke Biomarker Selection

• Stroke biomarker discovery. We use advanced technologies to find the most relevant stroke biomarkers to achieve your goals, including ELISA, aptamer-based assays, mass spectrometry, 2D gel electrophoresis, RT-PCR, microarray, and sequencing.
• Statistical analysis. We use methods such as logistic regression to determine which biomarkers differ significantly between stroke animal models and controls.
• Feature selection techniques. We use a variety of feature selection methods to identify the most effective combination of stroke biomarkers. These methods include forward selection, backward selection, or combining markers into families, clusters or networks based on expression patterns and/or biological information.

Predictive Model Development and Validation

We offer multiple methods (e.g., nearest centroid, k-nearest neighbor, discriminate analysis, support vector machines, partial least squares, logistic regression, or random forests) for combining selected stroke biomarkers into predictive models. These models are designed to combine information from multiple stroke biomarkers to improve diagnostic performance. We also use cross-validation or bootstrapping techniques to validate the stroke biomarker panel.

Evaluation and Validation of Biomarker Panels in Animal Models of Stroke

We provide reliable animal models of stroke to characterize the efficacy of applying these biomarker panels in diagnosing stroke and identifying stroke etiology. Our services include validating effective biomarker panels we develop by comparing the results of cognitive testing/histological analysis with those of the panel.

Ace Therapeutics has the specialized tools and expertise to successfully advance your biomarker panel development program. By integrating multiple biomarkers, these panels can better reflect the multiple pathophysiologies involved in stroke. Please do not hesitate to contact us if you have any questions.

1. Dagonnier, M., et al. (2021). Acute stroke biomarkers: are we there yet? Frontiers in neurology, 12, 619721.